Sugi Predict

Sugi Predict / Compounds / SCHEMBL1427263

SCHEMBL1427263

SCHEMBL1427263

COC(=O)c1c[nH]c2ncc(Br)cc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 5/20 0.63
▸ NR4A2 P43354 10/20 0.58
▸ MAP2K1 Q02750 1/20 0.56
▸ PLK4 O00444 1/20 0.46
▸ AURKA O14965 1/20 0.46
▸ JAK2 O60674 1/20 0.46
▸ ROCK2 O75116 1/20 0.46
▸ PRKD3 O94806 1/20 0.46
▸ MAP4K4 O95819 1/20 0.46
▸ PRKCG P05129 1/20 0.46
▸ INSR P06213 1/20 0.46
▸ CDK1 P06493 1/20 0.46
▸ FES P07332 1/20 0.46
▸ IGF1R P08069 1/20 0.46
▸ ROS1 P08922 1/20 0.46
▸ FGFR1 P11362 1/20 0.46
▸ PHKG2 P15735 1/20 0.46
▸ FER P16591 1/20 0.46
▸ FLT1 P17948 1/20 0.46
▸ CDK2 P24941 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30676600 1.00 AXL (0.63) AXLNR4A2MAP2K1PLK4AURKA
SCHEMBL10131658 0.90 AXL (0.52) AXLNR4A2MAP2K1PLK4AURKA
SCHEMBL12409372 0.86 GABRA1 (0.53) AXLNR4A2JAK2JAK3TSHR
SCHEMBL28696802 0.85 AXL (0.47) AXLNR4A2MAP2K1PLK4AURKA
SCHEMBL1516568 0.84 DYRK1A (0.48) AXLNR4A2MAP2K1PLK4AURKA
SCHEMBL28046056 0.84 BRAF (0.53) AXLNR4A2MAP2K1PLK4AURKA
SCHEMBL4828101 0.84 AURKA (0.54) AXLNR4A2MAP2K1PLK4AURKA
SCHEMBL9938466 0.83 AXL (0.64) AXLNR4A2MAP2K1CREBBPBRAF
SCHEMBL4120005 0.82 SYK (0.46) AXLNR4A2MAP2K1PLK4AURKA
SCHEMBL9938142 0.82 AXL (0.63) AXLNR4A2MAP2K1CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108997340-B Synthetic method of 5-bromo-7-azaindole 山东轩德医药科技有限公司 2020-03-20 — — CN claimed
US-20260035373-A1 PYRROLOPYRIMIDINE ITK INHIBITORS ACLARIS THERAPEUTICS INC (US) 2026-02-05 — — US disclosed
US-12486264-B2 Bicyclic HPK1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2025-12-02 — — US disclosed
US-20250263491-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES ABBVIE INC (US) 2025-08-21 — — US disclosed
US-12297203-B2 Pyrrolopyrimidine ITK inhibitors ACLARIS THERAPEUTICS, INC. (US) 2025-05-13 — — US disclosed
CN-119080779-A Pyrrolopyrimidine ITK inhibitors 阿克拉瑞斯治疗股份有限公司 2024-12-06 — — CN disclosed
CN-112823005-B Pyrrolopyrimidine ITK inhibitors 阿克拉瑞斯治疗股份有限公司 2024-08-20 — — CN disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 — — US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 — — US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 — — US disclosed
EP-2300475-B1 DIAZACARBAZOLES AND METHODS OF USE GENENTECH INC (US) 2014-11-05 — — EP disclosed
EP-2706059-A1 Diazacarbazoles and methods of use Genentech, Inc. (US) 2014-03-12 — — EP disclosed
US-20130261104-A1 METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER GENENTECH, INC. (US) 2013-10-03 — — US disclosed
US-8501765-B2 Diazacarbazoles and methods of use GENENTECH, INC. (US) 2013-08-06 — — US disclosed
US-20110118230-A1 DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. 2011-05-19 — — US disclosed
EP-2300475-A1 DIAZACARBAZOLES AND METHODS OF USE Genentech, Inc. (US) 2011-03-30 — — EP disclosed
WO-2009151598-A1 DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. (US) 2009-12-17 — — WO disclosed
US-20090018130-A1 Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid ASTRAZENECA AB (SE) 2009-01-15 — — US disclosed
EP-1761530-A1 NEW DERIVATIVES OF 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXAMIDE OR 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXYLIC ACID AstraZeneca AB (SE) 2007-03-14 — — EP disclosed
WO-2006001754-A1 NEW DERIVATIVES OF 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXAMIDE OR 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXYLIC ACID ASTRAZENECA AB (SE) 2006-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035373-A1 PYRROLOPYRIMIDINE ITK INHIBITORS JAK3, JAK1, JAK2 AXL 1140/4885NR4A2 725/4885MAP2K1 52/4885
US-12486264-B2 Bicyclic HPK1 inhibitors PCK1, PGK1, PDXK AXL 4496/4885NR4A2 3018/4885MAP2K1 485/4885
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 KLK5, KLK1, KLKB1 AXL 4839/4885NR4A2 2887/4885MAP2K1 715/4885
US-20110118230-A1 DIAZACARBAZOLES AND METHODS OF USE CHEK1, CHEK2, BUB1B AXL 1073/4885NR4A2 3598/4885MAP2K1 514/4885
US-20090018130-A1 Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid AADAC, PAH, PDE7A AXL 2020/4885NR4A2 3018/4885MAP2K1 4298/4885
US-20250263491-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES EGFR, ERBB2, ERBB3 AXL 850/4885NR4A2 4293/4885MAP2K1 1024/4885
US-12297203-B2 Pyrrolopyrimidine ITK inhibitors ITK, PDXK, DMPK AXL 3254/4885NR4A2 1620/4885MAP2K1 713/4885
US-20130261104-A1 METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER IDH3B, IDH3A, EGLN3 AXL 3414/4885NR4A2 1584/4885MAP2K1 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.